$0.01 EPS Expected for Vertex Pharmaceuticals Incorporated (VRTX)

October 1, 2017 - By Clifton Ray

Investors sentiment increased to 1.51 in Q2 2017. Its up 0.20, from 1.31 in 2017Q1. It is positive, as 31 investors sold Vertex Pharmaceuticals Incorporated shares while 154 reduced holdings. 98 funds opened positions while 181 raised stakes. 231.33 million shares or 0.08% less from 231.51 million shares in 2017Q1 were reported.
Northcoast Asset Management Ltd Limited Liability Company reported 6,069 shares. Brinker Capital holds 12,232 shares. Cambridge Inv Advisors holds 0.01% or 6,383 shares. Benjamin F Edwards And stated it has 0% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). National Asset Mngmt Inc reported 1,859 shares or 0.04% of all its holdings. Nationwide Fund Advsrs owns 116,511 shares for 0.06% of their portfolio. Schroder Invest Mngmt reported 0.01% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Amp Capital Invsts Ltd invested in 0.08% or 104,764 shares. Caisse De Depot Et Placement Du Quebec holds 0% or 7,805 shares in its portfolio. Susquehanna Grp Llp has invested 0% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Camber Capital Mngmt Lc has 2.2% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 350,000 shares. First Personal Serv holds 10 shares or 0% of its portfolio. Tekla Management Ltd Liability Corp owns 798,053 shares. Rnc Capital Ltd Com stated it has 2,978 shares. Rhenman Prtn Asset Mngmt Ab holds 95,013 shares or 1.76% of its portfolio.

Since April 3, 2017, it had 0 insider buys, and 17 selling transactions for $53.00 million activity. $249,384 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Chodakewitz Jeffrey on Monday, April 3. Shares for $9.09M were sold by Arbuckle Stuart A on Thursday, June 1. ALTSHULER DAVID sold $900,000 worth of stock. $13,267 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Sachdev Amit. $151,045 worth of stock was sold by Bhatia Sangeeta N. on Thursday, June 1. Silva Paul M sold $31,067 worth of stock or 271 shares.

Analysts expect Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report $0.01 EPS on October, 24.They anticipate $0.10 EPS change or 111.11 % from last quarter’s $-0.09 EPS. VRTX’s profit would be $2.52 million giving it 3801.00 P/E if the $0.01 EPS is correct. After having $0.10 EPS previously, Vertex Pharmaceuticals Incorporated’s analysts see -90.00 % EPS growth. The stock increased 1.62% or $2.42 on September 29, reaching $152.04. About 1.50 million shares traded or 2.04% up from the average. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since October 1, 2016 and is uptrending. It has outperformed by 28.99% the S&P500.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

Among 25 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 21 have Buy rating, 0 Sell and 4 Hold. Therefore 84% are positive. Vertex Pharmaceuticals had 70 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Outperform” rating by Cowen & Co given on Wednesday, July 19. The rating was maintained by Jefferies with “Buy” on Friday, June 9. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Buy” rating given on Tuesday, September 26 by Leerink Swann. The company was upgraded on Wednesday, March 29 by BMO Capital Markets. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by Vetr on Tuesday, September 1. The company was maintained on Wednesday, October 5 by Jefferies. The rating was initiated by Oppenheimer with “Perform” on Thursday, December 15. As per Wednesday, July 19, the company rating was maintained by Jefferies. The stock has “Neutral” rating by Goldman Sachs on Thursday, April 28. H.C. Wainwright downgraded it to “Neutral” rating and $85 target in Monday, October 24 report.

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The company has market cap of $38.33 billion. The Firm is focused on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs in other indications. It has a 147.16 P/E ratio. The Company’s marketed medicines are ORKAMBI and KALYDECO.

More notable recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: Benzinga.com which released: “3 Reasons To Like Vertex Pharma Shares” on September 29, 2017, also Seekingalpha.com with their article: “Vertex Pharmaceuticals Looks To Push The Envelope” published on July 19, 2017, Fool.com published: “Vertex Pharmaceuticals results: The raw numbers” on July 28, 2017. More interesting news about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were released by: Investorplace.com and their article: “Vertex Pharmaceuticals Incorporated (VRTX) Stock Is Too Expensive” published on August 21, 2017 as well as Seekingalpha.com‘s news article titled: “Vertex Pharmaceuticals May Be Turning Some Major Corners” with publication date: August 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com